Hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine: a review of HEPLISAV™ safety and efficacy
Hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine: a review of HEPLISAV™ safety and efficacy
复制标题
DOI：
10.1586/erv.10.162
复制
发表时间：
2011-04-01
影响因子：
6.2
通讯作者：
Mackie, David
中科院分区：
文献类型：
--
作者：
Cooper, Curtis;Mackie, David
免疫接种是预防B型肝炎病毒感染和慢性病长期并发症（包括肝癌和肝功能衰竭）的最有效方法。目前的疫苗需要三剂才能达到最大的免疫原性，并且不能在5-10%的免疫能力强的个体和更大比例的免疫受损患者中产生持久的保护。免疫刺激性DNA序列（ISS）疫苗佐剂，当与疫苗抗原组合时，可以增加免疫原性并减少实现该目标所需的剂量数。已证明1018 ISS加重组B型肝炎表面抗原可在免疫能力强和疫苗低应答人群中实现这些目标，而不会影响受者安全性。
Immunization represents the most effective approach to the prevention of hepatitis B virus infection and the long-term complications of chronic disease, including liver cancer and liver failure. Current vaccines require three doses to achieve maximal immunogenicity and fail to produce long-lasting protection in 5-10% of immune-competent individuals and in a much larger proportion of immune-compromised patients. Immunostimulatory DNA sequence (ISS) vaccine adjuvants, when combined with vaccine antigens, may increase immunogenicity and reduce the number of required doses to achieve this goal. 1018 ISS plus recombinant hepatitis B surface antigen has been demonstrated to achieve these goals in immune competent and vaccine-hyporesponsive populations without compromising recipient safety.